Search Results
The product title you are looking for is no longer available. Other similar products that may interest you are listed below:
Refine your Search
|
Title
|
Publication Date
|
Price
|
Relevance
|
|
Swedish Orphan Biovitrum AB (formerly Biovitrum AB)-Detailed Product Pipeline
|
Mar 2011 |
£475 |
100% |
|
Swedish Orphan Biovitrum AB (formerly Biovitrum AB)-Therapeutic Competitors Report
|
Mar 2011 |
£220 |
99% |
|
Swedish Orphan Biovitrum AB (formerly Biovitrum AB)-Deals & Alliances Report
|
Mar 2011 |
£380 |
99% |
Medivir AB – Product Pipeline Review
H2 2011
|
Nov 2011 |
£315 |
73% |
Mucositis Global Clinical Trials Review
H2, 2011
|
Nov 2011 |
£630 |
72% |
Growth Disorders - Pipeline Review
H2 2011
|
Sep 2011 |
£315 |
72% |
Squamous Cell Carcinoma Global Clinical Trials Review
Q4, 2010
|
Dec 2010 |
£630 |
70% |
Head and Neck Cancer Global Clinical Trials Review
H2, 2011
|
Dec 2011 |
£630 |
68% |
Graft Versus Host Disease (GVHD) Global Clinical Trials Review
Q1, 2011
|
Mar 2011 |
£630 |
67% |
Biologic Therapeutic Drugs
Technologies and Global Markets
|
Jan 2011 |
£3,065 |
57% |
The Future of the Biologicals Market
Market overview, innovations and company profiles
|
Mar 2010 |
£2,425 |
55% |
|
Biogen Idec: Pipeline - Products - Performance - Potential
|
Jan 2010 |
£595 |
52% |
|
Amgen: Pipeline • Products • Performance • Potential
|
Nov 2010 |
£595 |
52% |
Anemia - Pipeline Review
H2 2011
|
Sep 2011 |
£315 |
50% |
|
Growth Factors ( Blood And Tissue )
|
Jan 2011 |
£2,845 |
50% |
Rheumatoid Arthritis: World Drug Market
2011-2021
|
Sep 2011 |
£1,699 |
49% |
The Future of Blood Disorders Therapeutics, Analysis and Market Forecasts to 2016
Better and More Cost-Effective Treatment Options Create Opportunities
|
Mar 2010 |
£2,215 |
44% |
Blood Disorders Therapeutics Market to 2017
Patent Expiries of Lovenox, Plavix, Procrit/Epogen, Aranesp and Neulasta Will Slow down Growth
|
Sep 2011 |
£2,215 |
44% |
